ROZLYTREK™ shrank tumors in many different types of cancer

ROZLYTREK was studied in 54 people with NTRK fusion-positive solid tumors across 3 clinical trials. These studies measured 2 things: how many people had their tumors shrink, and the length of time that response lasted. People who had NTRK fusion-positive solid tumors that spread to the brain were also included in the trials. The trials did not compare ROZLYTREK to another medication.

ROZLYTREK was studied in people with a range of cancer types, including

More than half of the people treated with ROZLYTREK had their tumors shrink

  • Of the people who had prior treatment for their cancer that had spread to other parts of the body, 53% of people had their tumors shrink, similar to what was seen in all patients
  • 68% (21 out of 31 people) had a response continue to at least 6 months
  • 61% (19 out of 31 people) had a response continue to at least 9 months
  • 45% (14 out of 31 people) had a response continue to at least 12 months

ROZLYTREK was shown to reduce cancer that had spread to the brain

In the same clinical trials, 4 of 54 people had NTRK fusion-positive solid tumors that had spread to the brain (known as CNS metastases) and did not have prior radiation therapy for these tumors (within 2 months of starting ROZLYTREK). The trials did not compare ROZLYTREK to another medication.

*It is important to know that tumor shrinkage does not mean the cancer has been cured.
CNS=central nervous system.

ROZLYTREK Financial Resources

Financial and other resources

Learn about financial and other resources to help you access ROZLYTREK™.

Getting ROZLYTREK

Getting ROZLYTREK

Learn about specialty pharmacy options.